Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 18M | 184.4% |
| Gross Profit | 18M | 184.4% |
| Operating expense | 36M | 0.3% |
| Net Income | -20M | 34.7% |
| EBITDA | -18M | 34.8% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 98M | 13.2% |
| Total Liabilities | 78M | 4.1% |
| Total Equity | 20M | 299.6% |
| Shares Outstanding | 257M | 16.7% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -18M | 30.6% |
| Cash from investing | -24,000 | 0% |
| Cash from financing | 29M | 251.8% |
EPS
Financial Highlights for Sangamo Therapeutics in Q2 '25
Sangamo Therapeutics reported a revenue of 18M, which is a 184.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 18M, marking a 184.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 36M, showing a 0.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -20M, showing a 34.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -18M, showing a 34.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Sangamo Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
